Shp1 phosphatase regulates CXCR2 protein stability and IL8-mediated invasiveness in breast cancer
Open Access
- 2 March 2026
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Abstract
Shp1 is a cytosolic tyrosine phosphatase generally associated with antitumor effects through the inhibition of tyrosine kinase signaling. Herein, we shown that genetic and pharmacological inhibition of Shp1 in breast cancer cells induces accelerated cell migration and promotes a more invasive phenotype. Furthermore, we found that interleukin-8 (IL8), a chemokine with multiple pro-tumorigenic roles within the tumor microenvironment, directly modulates Shp1 activity. In breast cancer, IL8 elicits its functions through the binding to the CXCR2 receptor with the subsequent modulation of several intracellular signaling pathways. We show that in breast MCF7 cells, IL8 induces the PKC-mediated phosphorylation of Shp1 at Ser591, diminishing its enzymatic activity and impairing the dephosphorylation of PP2A; this enhances CXCR2 phosphorylation and alters receptor trafficking by promoting ubiquitination and degradation of CXCR2. This feedback mechanism limits IL8 signaling revealing a previously unrecognized mechanism of receptor turnover and signal attenuation. In addition, we found that Shp1-mediated regulation of CXCR2 directly influences IL8-driven invasiveness in a subtype-specific manner, affecting luminal and triple-negative breast cancer (TNBC) cells but not HER2-positive ones. Transcriptomic and pathway analyses further support Shp1 involvement in cytokine and GPCR signaling, particularly in TNBC, where its downregulation correlates with reduced survival and higher IL8 levels. Taken together, our findings elucidate a novel mechanism of IL8 signaling and identify Shp1 as a promising therapeutic target, highlighting the potential of modulating the CXCR2–Shp1 axis to limit invasiveness and metastasis in aggressive breast cancer subtypes, particularly TNBC.Keywords
This publication has 62 references indexed in Scilit:
- Research progress of SHP-1 agonists as a strategy for tumor therapyMolecular Diversity, 2024
- Current and future burden of breast cancer: Global statistics for 2020 and 2040The Breast, 2022
- Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapyCancer Letters, 2020
- New insights into the regulation of the actin cytoskeleton dynamics by GPCR/β-arrestin in cancer invasion and metastasis2019
- Sorafenib analogue SC‐60 induces apoptosis through the SHP‐1/STAT3 pathway and enhances docetaxel cytotoxicity in triple‐negative breast cancer cellsMolecular Oncology, 2017
- Recurrent read-through fusion transcripts in breast cancerBreast Cancer Research and Treatment, 2014
- The tyrosine phosphatase SHP-1 inhibits proliferation of activated hepatic stellate cells by impairing PDGF receptor signalingBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2014
- Advanced glycation end product Nε‐carboxymethyllysine induces endothelial cell injury: the involvement of SHP‐1‐regulated VEGFR‐2 dephosphorylationThe Journal of Pathology, 2012
- Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformationJournal of Cellular Biochemistry, 2011
- SHP‐1 suppresses cancer cell growth by promoting degradation of JAK kinasesJournal of Cellular Biochemistry, 2003